- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma : Episode 2
Opinion
Video
Utility of Molecular Testing in Skin Cancer Risk Assessment
Author(s):
An expert discusses the qualities of genetic tests that are most important to clinicians seeking precise and reliable results for melanoma diagnosis and prognosis, and reviews the 31-gene expression profile (GEP) test, highlighting its ability to classify melanoma risk into 1A, 1B, 2A, and 2B, with 1A patients showing higher melanoma-specific survival (MSS) and overall survival (OS), while 1B/2A and 2B classifications serve as independent predictors of MSS and OS, noting that patients who underwent 31-GEP testing had lower mortality compared with untested patients.
Video Player is loading.
Video content above is prompted by the following:
- Various gene expression profiles have been studied for the diagnosis of melanoma (such as the 2- or 3-GEP pigmented lesion assay) as well as for melanoma prognosis (including the 31-GEP and 8-GEP tests). Biomarkers, including lactate dehydrogenase and circulating tumor DNA (ctDNA) have also been investigated in melanoma classification strategies. What qualities of a particular genetic test are most important to clinicians seeking precise and reliable results?
- Discuss the following GEP/biomarker tests for melanoma:
- 31-GEP test
- Classifies risk into 1A, 1B, 2A, or 2B
- 1A patients have a higher MSS and OS compared with 1B/2A and 2B
- 1B/2A and 2B classification were independent predictors of MSS and OS
- Patients who underwent 31-GEP testing had lower MSS mortality and overall mortality when compared with untested patients
Related Videos
Limitations and Challenges in Skin Cancer Staging Systems
Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis
Mechanism of Action Differences Among IL-17 Inhibitors
The Role of IL-17 in Psoriasis Pathogenesis
Navigating the Boxed Warning for the JAK Inhibitor Class
Personalized Photoprotection Based on Patient Factors
Impact of Oxidative Stress on Skin Health and the Utility of Antioxidants
Laboratory Monitoring for JAK Inhibitors and Key Takeaways
Options for Eyebrow and Eyelash Regrowth in a 32-Year-Old Female With Alopecia Areata
Efficacy, Safety, and Role in Therapy of JAK Inhibitors for Atopic Dermatitis
Related Content
